Fumitaka Suto
Research Subjects
Fumitaka Suto has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Yusuke Kuwahara
Daiichi Sankyo, Basking Ridge, USA
11 shared publications - Makito Koga
Daiichi Sankyo, Co., Ltd, Tokyo, Japan
10 shared publications - Kohei Shitara
National Cancer Center East, Kashiwa, Japan
9 shared publications - Akihito Kawazoe
Department of Gastroenterology and Gastrointestinal oncology National Cancer Center Hospital East Chiba Japan
8 shared publications - Hiroki Goto
Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo 134-0081, Japan
8 shared publications - Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
8 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2500823
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer
PURPOSE: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA). Eligibility for T-DXd therapy currently relies on conventional HER2 immunohistochemistry (IHC) scoring per ASCO/CAP guidelines. Computational pathology tools such as quantitative continuous scoring (QCS) offer precise quantification of HER2 expression, enabling improved scores reflective of T-DXd's mechanism of action. METHODS: We used HER2-QCS scoring to identify biomarker signatures in the DESTINY-Gastric01 cohort, with external validation in DESTINY-Gastric02. RESULTS: QCS-derived continuous spatial proximity score (cSPS) and density of HER2-positive cells in tumor epithelium (DPC) displayed significant survival benefits for biomarker-positive versus biomarker-negative patients in the DESTINY-Gastric01 T-DXd arm (Cox regression: P < .0001). These signatures were validated in the DESTINY-Gastric02 cohort (log-rank P < .0001). CONCLUSION: Our findings indicate that cSPS and DPC are predictive of T-DXd clinical outcomes, supporting the potential future use of QCS as a quantitative approach to identify patients with GC who might benefit most from T-DXd therapy.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2500823
Open AccessHuman Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer
PURPOSE: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA). Eligibility for T-DXd therapy currently relies on conventional HER2 immunohistochemistry (IHC) scoring per ASCO/CAP guidelines. Computational pathology tools such as quantitative continuous scoring (QCS) offer precise quantification of HER2 expression, enabling improved scores reflective of T-DXd's mechanism of action. METHODS: We used HER2-QCS scoring to identify biomarker signatures in the DESTINY-Gastric01 cohort, with external validation in DESTINY-Gastric02. RESULTS: QCS-derived continuous spatial proximity score (cSPS) and density of HER2-positive cells in tumor epithelium (DPC) displayed significant survival benefits for biomarker-positive versus biomarker-negative patients in the DESTINY-Gastric01 T-DXd arm (Cox regression: P < .0001). These signatures were validated in the DESTINY-Gastric02 cohort (log-rank P < .0001). CONCLUSION: Our findings indicate that cSPS and DPC are predictive of T-DXd clinical outcomes, supporting the potential future use of QCS as a quantitative approach to identify patients with GC who might benefit most from T-DXd therapy.
- Open Access
- 4 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3492-3503
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Antibody–drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2− metastatic breast cancer, who previously progressed on CDK4/6 inhibitors and one line of chemotherapy. From May 2021 to June 2023, 99 patients were enrolled to receive HER3-DXd 5.6 mg kg−1 intravenously every 3 weeks. The study met its primary endpoint, showing an overall response rate of 53.5% (90% confidence interval [44.8–62.1%]). The most frequent adverse events were fatigue (83%), nausea (75%), diarrhea (53%) and alopecia (40%). Exploratory biomarker analysis of baseline tumor samples suggested preliminary associations between overall response rate and both HER3 spatial distribution and absence of estrogen receptor 1 (ESR1) mutations, as well as between progression-free survival and HER3 expression, pending further validation. Analysis of on-treatment tumor samples showed that treatment efficacy seems to be associated with antibody–drug conjugate intratumoral distribution and interferon response. Overall, HER3-DXd showed promising activity and manageable tolerability in patients with HR+HER2− metastatic breast cancer who progressed on CDK4/6 inhibitors. These findings highlight the need for larger trials to define HER3-DXd efficacy relative to other drugs, including antibody–drug conjugates (ClinicalTrials.gov Identifier: NCT04965766).
- 4 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3492-3503
Open AccessPatritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Antibody–drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2− metastatic breast cancer, who previously progressed on CDK4/6 inhibitors and one line of chemotherapy. From May 2021 to June 2023, 99 patients were enrolled to receive HER3-DXd 5.6 mg kg−1 intravenously every 3 weeks. The study met its primary endpoint, showing an overall response rate of 53.5% (90% confidence interval [44.8–62.1%]). The most frequent adverse events were fatigue (83%), nausea (75%), diarrhea (53%) and alopecia (40%). Exploratory biomarker analysis of baseline tumor samples suggested preliminary associations between overall response rate and both HER3 spatial distribution and absence of estrogen receptor 1 (ESR1) mutations, as well as between progression-free survival and HER3 expression, pending further validation. Analysis of on-treatment tumor samples showed that treatment efficacy seems to be associated with antibody–drug conjugate intratumoral distribution and interferon response. Overall, HER3-DXd showed promising activity and manageable tolerability in patients with HR+HER2− metastatic breast cancer who progressed on CDK4/6 inhibitors. These findings highlight the need for larger trials to define HER3-DXd efficacy relative to other drugs, including antibody–drug conjugates (ClinicalTrials.gov Identifier: NCT04965766).
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- Open Access
- 15 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
- 15 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessPublisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Data from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted.Significance:This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted.Significance:This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Immune infiltration in tumors at baseline and association with response to T-DXd therapy. A, Tumoral CD8+ cell densities, as determined using mIHC, at baseline in responders and nonresponders. B, CD8A and CD8B mRNA expression levels, as determined using RNA-seq, in responders and nonresponders. CPM, counts per million. C, Relationship between immune cell densities for cells expressing CD4, CD68, CD20, CD163, CD208, and CD1a, as determined using mIHC and IHC. D, Relationship between immune cell densities and T-DXd efficacy. Patients with high vs. low immune cell densities were grouped based on the median value.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Immune infiltration in tumors at baseline and association with response to T-DXd therapy. A, Tumoral CD8+ cell densities, as determined using mIHC, at baseline in responders and nonresponders. B, CD8A and CD8B mRNA expression levels, as determined using RNA-seq, in responders and nonresponders. CPM, counts per million. C, Relationship between immune cell densities for cells expressing CD4, CD68, CD20, CD163, CD208, and CD1a, as determined using mIHC and IHC. D, Relationship between immune cell densities and T-DXd efficacy. Patients with high vs. low immune cell densities were grouped based on the median value.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Unsupervised hierarchical clustering analysis based on cell densities of evaluated immune cells at baseline. A, Heatmap depicting unsupervised hierarchical clustering results and characteristics of the three observed groups. B, ERBB2 expression levels in the three groups obtained from clustering. C, Kaplan–Meier OS and PFS curves of groups 1, 2, and 3 grouped by unsupervised hierarchical clustering based on cell densities of the evaluated immune cells. CPM, counts per million; ECOG PS, Eastern Cooperative Oncology Group performance status; I/O, immunotherapy.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Unsupervised hierarchical clustering analysis based on cell densities of evaluated immune cells at baseline. A, Heatmap depicting unsupervised hierarchical clustering results and characteristics of the three observed groups. B, ERBB2 expression levels in the three groups obtained from clustering. C, Kaplan–Meier OS and PFS curves of groups 1, 2, and 3 grouped by unsupervised hierarchical clustering based on cell densities of the evaluated immune cells. CPM, counts per million; ECOG PS, Eastern Cooperative Oncology Group performance status; I/O, immunotherapy.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Tumor-infiltrating immune cell densities at baseline and in response to T-DXd therapy in responders and nonresponders. A, Tumor-infiltrating CD8+ T-cell densities, as determined using mIHC. B, Tumoral CD8A and CD8B expression, as determined using RNA-seq. C, Percentage of CD8+ cells in CD3+ at baseline, as determined using FCM. D, Densities of eTregs (Fr2) and PD-1+CD8+ T cells and the CD8+ T-cell/eTreg ratio (Fr2). BL, baseline; CPM, copies per million; eTreg, effector Treg; OnT, on treatment.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Tumor-infiltrating immune cell densities at baseline and in response to T-DXd therapy in responders and nonresponders. A, Tumor-infiltrating CD8+ T-cell densities, as determined using mIHC. B, Tumoral CD8A and CD8B expression, as determined using RNA-seq. C, Percentage of CD8+ cells in CD3+ at baseline, as determined using FCM. D, Densities of eTregs (Fr2) and PD-1+CD8+ T cells and the CD8+ T-cell/eTreg ratio (Fr2). BL, baseline; CPM, copies per million; eTreg, effector Treg; OnT, on treatment.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Associations between pretreatment HER2 expression levels and therapy response to T-DXd. A, ERBB2 mRNA expression levels, as determined using RNA-seq. B, HER2 H-score, as determined using IHC. CPM, counts per million; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Associations between pretreatment HER2 expression levels and therapy response to T-DXd. A, ERBB2 mRNA expression levels, as determined using RNA-seq. B, HER2 H-score, as determined using IHC. CPM, counts per million; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.